Last updated on August 2017

To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors


Brief description of study

The purpose of this study is to find the safe dose of nab-paclitaxel in children with solid tumors, and to see if it works to treat these solid tumors in children and young adults (in phase 1 ≤ 18 years old and in phase 2 ≤ 24 years old). After the final dose has been chosen, patients will be enrolled according to the specific solid tumor type, (neuroblastoma, rhabdomyosarcoma, or Ewing's sarcoma), to see how nab-paclitaxel works in treating these tumors.

Detailed Study Description

ABI-007-PST-001 is a Phase 1 / 2, multicenter, open-label, dose-finding study to assess the safety , tolerability, and preliminary efficacy of weekly nab-paclitaxel in pediatric patients with recurrent or refractory solid tumors (excluding brain tumors). The Phase 1 portion of the study, with a dose escalation design, ended and the recommended Phase 2 dose (RP2D) was determined as 240 mg/m2 IV in patients weighing > 10 kg and 11.5 mg/kg in patients weighing ≤ 10 kg on Days 1, 8 and 15 of a 28-day cycle . The Phase 2 portion of the study will enroll additional patients at the RP2D into one of three solid tumor groups [Neuroblastomas, Rhabdomyosarcomas, Ewing's Sarcomas]. Both phases of the study are open-label and conducted at multiple centers. The Phase 2 is using a Simon two-stage design to monitor patient enrollment for each group separately. The Rhabdomyosarcoma group did not reach the expected number of two responders out of fourteen efficacy eligible patients. Consequently, this group is stopped.

Clinical Study Identifier: NCT01962103

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Associate Director Clinical Trial Disclosure

Phoenix Childrens Hospital
Phoenix, AZ United States
  Connect »

Associate Director Clinical Trial Disclosure

Columbia University Medical Center
New York, NY United States
  Connect »

Associate Director Clinical Trial Disclosure

The Hospital for Sick Children
Toronto, ON Canada
  Connect »

Associate Director Clinical Trial Disclosure

Institute for Pediatric Hemato-Oncology, Leon Berard Cancer Center
Lyon, France
  Connect »

Associate Director Clinical Trial Disclosure

Hopital d'Enfants, CHU Nancy
Nancy, France
  Connect »

Associate Director Clinical Trial Disclosure

Institut Gustave Roussy
Villejuif, France
  Connect »

Associate Director Clinical Trial Disclosure

Azienda Ospedaliera Universitaria Meyer
Firenze, Italy
  Connect »

Associate Director Clinical Trial Disclosure

Children's Hospital Largo
Genova, Italy
  Connect »

Associate Director Clinical Trial Disclosure

Istituto Nazionale Tumori
Milan, Italy
  Connect »

Associate Director Clinical Trial Disclosure

Clinica di Oncoematologia
Padova, Italy
  Connect »

Associate Director Clinical Trial Disclosure

Policlinico Agostino Gemelli
Rome, Italy
  Connect »

Associate Director Clinical Trial Disclosure

l'Azienda Ospedaliera Regina Margherita - Sant Anna
Torino, Italy
  Connect »

Associate Director Clinical Trial Disclosure

Hospital Universitario Vall D Hebron
Barcelona, Spain
  Connect »

Associate Director Clinical Trial Disclosure

Hospital Sant Joan de Deu
Barcelona, Spain
  Connect »

Associate Director Clinical Trial Disclosure

Spanish National Cancer Research Centre
Madrid, Spain
  Connect »

Associate Director Clinical Trial Disclosure

Hospital Universitario Virgen Del Rocio
Sevilla, Spain
  Connect »

Associate Director Clinical Trial Disclosure

Unidad de Oncologia Pediatrica, Hospital Universitario la Fe
Valencia, Spain
  Connect »

Associate Director Clinical Trial Disclosure

Universit ts-Kinderklinik
Zurich, Switzerland
  Connect »

Associate Director Clinical Trial Disclosure

Royal Marsden Hospital
Sutton, United Kingdom
  Connect »